6 quiz questions available for this topicTake Quiz

Coeliac disease

SNOMED: 391475007912 wordsUpdated 03/03/2026
💡

Exam Tips

  • Always test while the patient is still consuming gluten; starting a gluten-free diet first can produce false-negative serology/biopsy.
  • A classic OSCE trap is isolated iron-deficiency anaemia with minimal GI symptoms: coeliac disease can present extra-intestinally.
  • Positive tTG-IgA with low total IgA needs IgG-based serology, not dismissal of the diagnosis.
  • Symptom improvement does not equal mucosal healing; ongoing follow-up is required.
  • Differentiate non-responsive coeliac disease (usually gluten contamination) from refractory coeliac disease (persistent villous atrophy despite strict diet for at least 12 months).
  • Type 2 refractory disease is a pre-lymphomatous state with markedly worse prognosis.

Definition

Coeliac disease is a chronic, immune-mediated systemic disorder triggered by dietary gluten (wheat, barley and rye) in genetically susceptible people, causing inflammatory small-bowel enteropathy. It is defined by a combination of compatible serology (coeliac-specific antibodies), characteristic duodenal histology (villous atrophy, crypt hyperplasia and increased intraepithelial lymphocytes), and clinical response to a strict gluten-free diet.

Pathophysiology

In people carrying HLA-DQ2 and/or HLA-DQ8, gluten-derived gliadin peptides are deamidated by tissue transglutaminase (tTG), increasing peptide binding to antigen-presenting cells and activating CD4+ T-cell responses in the lamina propria. This drives cytokine-mediated mucosal inflammation, crypt hyperplasia and villous atrophy, reducing absorptive surface area and causing malabsorption (iron, folate, vitamin B12, calcium and vitamin D deficiencies). Autoantibody formation (anti-tTG IgA, endomysial antibodies) reflects the adaptive immune process; epithelial injury is amplified by intraepithelial lymphocyte activation. Proximal small bowel is often most affected first, which explains early iron deficiency. See Figure: Marsh-Oberhuber histological spectrum (intraepithelial lymphocytosis to subtotal/total villous atrophy).

Risk Factors

  • First-degree relative with coeliac disease (lifetime risk approximately 10-15%; higher in affected siblings)
  • HLA-DQ2 or HLA-DQ8 haplotypes
  • Personal autoimmune disease (especially type 1 diabetes mellitus, autoimmune thyroid disease)
  • Female sex
  • Any age can be affected, with peaks in early childhood (post-weaning) and early adulthood
  • Possible environmental contributors: gastrointestinal infections, higher gluten exposure, microbiome perturbation

Clinical Features

Symptoms

  • Chronic or intermittent diarrhoea
  • Bloating, abdominal discomfort, excess flatus
  • Weight loss or difficulty maintaining weight
  • Fatigue (often from iron deficiency anaemia)
  • Nausea or dyspepsia
  • Constipation (less typical but possible)
  • Aphthous mouth ulcers
  • Symptoms of micronutrient deficiency (e. g, paraesthesia from B12 deficiency)
  • Reduced fertility, recurrent miscarriage, menstrual disturbance
  • Pruritic blistering rash suggestive of dermatitis herpetiformis

Signs

  • Pallor (iron/folate/B12 deficiency anaemia)
  • Weight loss or low BMI
  • Abdominal distension
  • Glossitis or angular cheilitis
  • Bruising or osteomalacic bone tenderness in severe malabsorption
  • Peripheral neuropathy or gait ataxia in extra-intestinal disease
  • Dermatitis herpetiformis on extensor surfaces and buttocks
  • In children: faltering growth and delayed puberty

Investigations

Total serum IgA with IgA tissue transglutaminase antibody (tTG-IgA) while patient remains on gluten:Positive tTG-IgA supports diagnosis; check total IgA to avoid false-negative interpretation in IgA deficiency
IgG-based serology (e. g, IgG deamidated gliadin peptide or IgG tTG) if IgA deficient:Useful alternative pathway when total IgA is low or absent
Upper GI endoscopy with multiple duodenal biopsies (including bulb):Villous atrophy, crypt hyperplasia, increased intraepithelial lymphocytes; confirms enteropathy and helps classify severity
HLA-DQ2/DQ8 genotyping:Presence supports susceptibility but is not diagnostic; absence makes coeliac disease unlikely
FBC, ferritin, folate, vitamin B12:Iron deficiency anaemia is common; folate/B12 deficiency may coexist
Bone profile, calcium, ALP, vitamin D, and DEXA when indicated:May show metabolic bone disease (osteopenia/osteoporosis) due to chronic malabsorption
LFTs:Mild transaminitis can occur and may improve on gluten-free diet
Follow-up coeliac serology:Falling antibody titres suggest dietary adherence, but symptom resolution does not guarantee mucosal healing

Management

Lifestyle Modifications

  • Lifelong strict gluten-free diet with specialist dietitian input (avoid wheat, barley, rye; assess oats for contamination/tolerance)
  • Do not start a gluten-free diet until diagnostic testing is completed unless specialist advice says otherwise
  • Education on hidden gluten, cross-contamination, label reading, and eating-out risk reduction
  • Screen and correct nutritional deficiencies; monitor weight, symptoms and psychosocial impact
  • Vaccination review if hyposplenism/asplenia suspected (pneumococcal, meningococcal, Haemophilus influenzae type b as appropriate)
  • Structured follow-up for adherence, persistent symptoms and risk of non-responsive/refractory disease

Pharmacological Treatment

Micronutrient replacement

  • Ferrous sulfate 200 mg orally two to three times daily (each 200 mg tablet contains approximately 65 mg elemental iron)
  • Folic acid 5 mg orally once daily (typically for around 4 months, then reassess)
  • Hydroxocobalamin 1 mg intramuscularly on alternate days until improvement if symptomatic deficiency, then maintenance 1 mg every 2-3 months
  • Colecalciferol loading regimens (e. g, total about 300,000 units over 6-10 weeks) followed by maintenance 800-2000 units daily if needed
  • Calcium carbonate providing 1-1.2 g elemental calcium daily if intake is inadequate

Replace according to documented deficiency and local protocol; investigate persistent deficiency despite treatment for ongoing gluten exposure or alternative pathology.

Dermatitis herpetiformis symptom control

  • Dapsone initially 25-50 mg once daily, titrated to lowest effective dose (commonly 50-100 mg daily)

Specialist initiation/monitoring recommended. Check G6PD before treatment; monitor FBC and LFTs due to risk of haemolysis, methaemoglobinaemia, agranulocytosis and hepatotoxicity. Use caution in significant cardiorespiratory disease and anaemia.

Refractory coeliac disease (specialist care)

  • Prednisolone (for example 20-40 mg daily then taper according to response)
  • Budesonide modified-release (specialist-selected in some centres)
  • Azathioprine adjunct in selected type 1 refractory disease

Reserved for confirmed refractory disease after exclusion of ongoing gluten exposure and other causes; requires gastroenterology oversight and malignancy surveillance.

Complications

  • Iron, folate and vitamin B12 deficiency anaemia
  • Osteopenia/osteoporosis and fragility fractures
  • Faltering growth and delayed puberty in children
  • Dermatitis herpetiformis
  • Neurological complications (peripheral neuropathy, gluten ataxia)
  • Reproductive complications (subfertility, miscarriage, fetal growth restriction, preterm birth)
  • Functional hyposplenism/asplenia with increased risk of severe infection by encapsulated organisms
  • Non-responsive coeliac disease and refractory coeliac disease (type 1 and type 2)
  • Ulcerative jejunitis (rare)
  • Malignancy risk increase, particularly enteropathy-associated T-cell lymphoma and small bowel adenocarcinoma

Prognosis

Most patients improve clinically within weeks to months of a strict gluten-free diet, but histological recovery may lag behind symptoms and may remain incomplete in some adults despite good adherence. Children generally heal faster than adults. Persistent symptoms after 6-12 months are usually due to ongoing gluten exposure, while true refractory coeliac disease is uncommon; type 2 refractory disease carries poorer survival and a high risk of enteropathy-associated T-cell lymphoma.

Sources & References

NICE Guidelines(1)

📖Textbook References(20)

  • David Randall PhD MRCP (Editor), John Booth PhD MRCP (Editor), K - Kumar and Clark's Clinical Medicine (2025, American Elsevier Publishing Co.) - libgen.li.pdf(pp. 1246, 1247)[context]
  • David Randall PhD MRCP (Editor), John Booth PhD MRCP (Editor), K - Kumar and Clark's Clinical Medicine (2025, American Elsevier Publishing Co.) - libgen.li.pdf(pp. 1806)[context]
  • David Randall PhD MRCP (Editor), John Booth PhD MRCP (Editor), K - Kumar and Clark's Clinical Medicine (2025, American Elsevier Publishing Co.) - libgen.li.pdf(pp. 1247)[context]
  • David Randall PhD MRCP (Editor), John Booth PhD MRCP (Editor), K - Kumar and Clark's Clinical Medicine (2025, American Elsevier Publishing Co.) - libgen.li.pdf(pp. 1323)[context]
  • David Randall PhD MRCP (Editor), John Booth PhD MRCP (Editor), K - Kumar and Clark's Clinical Medicine (2025, American Elsevier Publishing Co.) - libgen.li.pdf(pp. 694)[context]
  • David Randall PhD MRCP (Editor), John Booth PhD MRCP (Editor), K - Kumar and Clark's Clinical Medicine (2025, American Elsevier Publishing Co.) - libgen.li.pdf(pp. 705, 706)[context]
  • David Randall PhD MRCP (Editor), John Booth PhD MRCP (Editor), K - Kumar and Clark's Clinical Medicine (2025, American Elsevier Publishing Co.) - libgen.li.pdf(pp. 682, 683)[context]
  • David Randall PhD MRCP (Editor), John Booth PhD MRCP (Editor), K - Kumar and Clark's Clinical Medicine (2025, American Elsevier Publishing Co.) - libgen.li.pdf(pp. 686)[context]
  • David Randall PhD MRCP (Editor), John Booth PhD MRCP (Editor), K - Kumar and Clark's Clinical Medicine (2025, American Elsevier Publishing Co.) - libgen.li.pdf(pp. 652)[context]
  • Guyton and Hall Textbook of Medical Physiology (John E. Hall, Michael E. Hall) (Z-Library).pdf(pp. 829)[context]
  • Guyton and Hall Textbook of Medical Physiology (John E. Hall, Michael E. Hall) (Z-Library).pdf(pp. 830, 831)[context]
  • Guyton and Hall Textbook of Medical Physiology (John E. Hall, Michael E. Hall) (Z-Library).pdf(pp. 829)[context]
  • Oxford Handbook of Clinical Diagnosis (Huw Llewelyn, Hock Aun Ang, Keir Lewis etc.) (Z-Library).pdf(pp. 357)[context]
  • [Oxford Medical Handbooks] Ian Wilkinson, Tim Raine, Kate Wiles, Anna Goodhart, Catriona Ha - Oxford Handbook of Clinical Medicine (2017, Oxford University Press) - libgen.li.pdf(pp. 343)[context]
  • [Oxford Medical Handbooks] Ian Wilkinson, Tim Raine, Kate Wiles, Anna Goodhart, Catriona Ha - Oxford Handbook of Clinical Medicine (2017, Oxford University Press) - libgen.li.pdf(pp. 874)[context]
  • [Oxford Medical Handbooks] Ian Wilkinson, Tim Raine, Kate Wiles, Anna Goodhart, Catriona Ha - Oxford Handbook of Clinical Medicine (2017, Oxford University Press) - libgen.li.pdf(pp. 261)[context]
  • [Oxford Medical Handbooks] Ian Wilkinson, Tim Raine, Kate Wiles, Anna Goodhart, Catriona Ha - Oxford Handbook of Clinical Medicine (2017, Oxford University Press) - libgen.li.pdf(pp. 343)[context]
  • [Oxford Medical Handbooks] Ian Wilkinson, Tim Raine, Kate Wiles, Anna Goodhart, Catriona Ha - Oxford Handbook of Clinical Medicine (2017, Oxford University Press) - libgen.li.pdf(pp. 342, 343)[context]
  • [Williams, Bailey and Love's Short Practice of Surgery] Norman Williams, Christopher Bulstrode, P Ronan O'Connell - Bailey & Love's Short Practice of Surgery 26E (2013, CRC Press) - libgen.li.pdf(pp. 1194)[context]
  • [Williams, Bailey and Love's Short Practice of Surgery] Norman Williams, Christopher Bulstrode, P Ronan O'Connell - Bailey & Love's Short Practice of Surgery 26E (2013, CRC Press) - libgen.li.pdf(pp. 1194)[context]

Test Your Knowledge

6 quiz questions available for this topic

Start Quiz